CommercialtodayNew
Likang Life Sciences Develops Personalized Cancer Vaccine with AI Technology - News and Statistics - IndexBox
Likang Life Sciences is completing a $16.1 million R&D and manufacturing center in Beijing by October, dedicated to its flagship personalized vaccine LK101. The facility will support an AI-assisted production line that analyzes patient tumor DNA to identify specific genetic mutations driving cancer. This infrastructure investment highlights the scaling of AI-driven neoantigen discovery capabilities within China's biotech sector.